Proton pump inhibitor is a risk factor for recurrence of common bile duct stones after endoscopic sphincterotomy – propensity score matching analysis

Abstract

Background and study aims Recurrence of common bile duct stones (CBDS) in patients treated with endoscopic sphincterotomy (ES) can lead to deterioration in their quality of life. Although the pathology and related factors are unclear, we speculated that proton pump inhibiter (PPI) administration increases the risk of CBDS recurrence by altering the bacterial mixture in the bile duct.

Patients and methods The primary endpoint of this retrospective study was recurrence-free period. Several independent variables considered to have a relationship with CBDS recurrence including PPI use were analyzed using a COX proportional hazard model, with potential risk factors then evaluated by propensity score matching analysis.

Results A total of 219 patients were analyzed, with CBDS recurrence found in 44. Analysis of variables using a COX proportional hazard model demonstrated that use of PPIs and ursodeoxycholic acid (UDCA), as well as the presence of periampullary diverticula (PD) each had a hazard ratio (HR) value greater than 1 (HR 2.2, P = 0.007; HR 2.0, P = 0.02; HR 1.9, P = 0.07; respectively). Furthermore, propensity score matching analysis revealed that the mean recurrence-free period in the oral PPI cohort was significantly shorter as compared with the non-PPI cohort (1613 vs. 2587 days, P = 0.014). In contrast, neither UDCA administration nor PD presence was found to be a significant factor in that analysis (1557 vs. 1654 days, P = 0.508; 1169 vs. 2011 days, P = 0.121; respectively).

Conclusion Our results showed that oral PPI administration is a risk factor for CBDS recurrence in patients who undergo ES.

• References

• 1 Classen M, Demling L. Endoscopic sphincterotomy of the papilla of vater and extraction of stones from the choledochal duct. Dtsch Med Wochenschr 1974; 99: 496-497
• 2 Kawai K, Akasaka Y, Murakami K. et al. Endoscopic sphincterotomy of the ampulla of Vater. Gastrointest Endosc 1974; 20: 148-151
• 3 Trikudanathan G, Arain MA, Attam R. et al. Advances in the endoscopic management of common bile duct stones. Nat Rev Gastroenterol Hepatol 2014; 11: 535-544
• 4 Saito M, Tsuyuguchi T, Yamaguchi T. et al. Long-term outcome of endoscopic papillotomy for choledocholithiasis with cholecystolithiasis. Gastrointest Endosc 2000; 51: 540-545
• 5 Ando T, Tsuyuguchi T, Okugawa T. et al. Risk factors for recurrent bile duct stones after endoscopic papillotomy. Gut 2003; 52: 116-121
• 6 Doi S, Yasuda I, Mukai T. et al. Comparison of long-term outcomes after endoscopic sphincterotomy versus endoscopic papillary balloon dilation: A propensity score-based cohort analysis. J Gastroenterol 2013; 48: 1090-1096
• 7 Lu Y, Wu J-C, Liu L. et al. Short-term and long-term outcomes after endoscopic sphincterotomy versus endoscopic papillary balloon dilation for bile duct stones. Eur J Gastroenterol Hepatol 2014; 26: 1367-1373
• 8 Kim KY, Han J, Kim HG. et al. Late complications and stone recurrence rates after bile duct stone removal by endoscopic sphincterotomy and large balloon dilation are similar to those after endoscopic sphincterotomy alone. Clin Endosc 2013; 46: 637-642
• 9 Sugiyama M, Atomi Y. Risk factors predictive of late complications after endoscopic sphincterotomy for bile duct stones: long-term (more than 10 years) follow-up study. Am J Gastroenterol 2002; 97: 2763-2767
• 10 Lam JR, Schneider JL, Zhao W. et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013; 310: 2435-2442
• 11 Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012; 28: 615-620
• 12 Leontiadis GI, Moayyedi P. Proton pump inhibitors and risk of bone fractures. Curr Treat Options Gastroenterol 2014; 12: 414-423
• 13 Lo W, Chan WW. Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 483-490
• 14 Lombardo L, Foti M, Ruggia O. et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010; 8: 504-508
• 15 Rosenbaum PR, Rubin DB, Central THE. et al. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55
• 16 Dehejia R, Wahba S. Propensity Score Matching Methods for Nonexperimental Studies. Rev Econ Stat 2002; 84: 151-161
• 17 Calmus Y, Poupon R. Ursodeoxycholic Acid (UDCA) in the treatment of chronic cholestatic diseases. Biochimie 1991; 73: 1335-1338
• 18 Guarino MPL, Cocca S, Altomare A. et al. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol 2013; 19: 5029-5034
• 19 Roma MG, Toledo FD, Boaglio AC. et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 2011; 121: 523-544
• 20 Akiyama S, Imamura T, Tamura T. et al. Recurrent common bile duct stones composed of ursodeoxycholic acid: A report of four cases. Intern Med 2014; 53: 2489-2492
• 21 Li X, Zhu K, Zhang L. et al. Periampullary diverticulum may be an important factor for the occurrence and recurrence of bile duct stones. World J Surg 2012; 36: 2666-2669
• 22 Kim CW, Chang JH, Kim JH. et al. Size and type of periampullary duodenal diverticula are associated with bile duct diameter and recurrence of bile duct stones. J Gastroenterol Hepatol 2013; 28: 893-898
• 23 Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56: S11-S17
• 24 Peng Y, Yang Y, Liu Y. et al. Cholesterol gallstones and bile host diverse bacterial communities with potential to promote the formation of gallstones. Microb Pathog 2015; 83 – 84: 57-63
• 25 Maki T. Pathogenesis of calcium bilirubinate gallstone: role of E. coli, beta-glucuronidase and coagulation by inorganic ions, polyelectrolytes and agitation. Ann Surg 1966; 164: 90-100
• 26 Yasuda I, Tomita E, Enya M. et al. Can endoscopic papillary balloon dilation really preserve sphincter of Oddi function?. Gut 2001; 49: 686-691
• 27 Toouli J. Sphincter of Oddi: Function, dysfunction, and its management. J Gastroenterol Hepatol 2009; 24 (Suppl. 03) S57-S62
• 28 Ishiguro J. Biliary bacteria as an indicator of the risk of recurrence of choledocholithiasis after endoscopic sphincterotomy. Diagn Ther Endosc 1998; 5: 9-17